Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06203210




Registration number
NCT06203210
Ethics application status
Date submitted
2/01/2024
Date registered
12/01/2024
Date last updated
22/04/2024

Titles & IDs
Public title
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Scientific title
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
Secondary ID [1] 0 0
2023-509628-16
Secondary ID [2] 0 0
DS7300-188
Universal Trial Number (UTN)
Trial acronym
IDeate-Lung02
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ifinatamab deruxtecan
Treatment: Drugs - Topotecan
Treatment: Drugs - Amrubicin
Treatment: Drugs - Lurbinectedin

Experimental: Ifinatamab deruxtecan (I-DXd) - Participants randomized to receive 12 mg/kg I-DXd monotherapy on Day 1 of each 21-day cycle until unacceptable toxicity, progressive disease (PD), or withdrawal of consent as specified in the protocol.

Active Comparator: Treatment of Physician's Choice (TPC) - Participants randomized to receive topotecan, lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label (indicated dose and frequency), until a treatment discontinuation criterion is met as specified in the protocol.


Treatment: Drugs: Ifinatamab deruxtecan
12 mg/kg intravenous dose on Day 1 of each 21-day cycle

Treatment: Drugs: Topotecan
Topotecan will be administered per local SoC.

Treatment: Drugs: Amrubicin
Amrubicin will be administered per local SoC.

Treatment: Drugs: Lurbinectedin
Lurbinectedin will be administered per local SoC
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Objective Response Rate Assessed by Blinded Independent Central Review
Timepoint [1] 0 0
Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 4.5 years
Primary outcome [2] 0 0
Overall Survival
Timepoint [2] 0 0
From the date of randomization to the date of death due to any cause, whichever occurs first, up to approximately 4.5 years
Secondary outcome [1] 0 0
Number of Participants With Objective Response Rate Assessed by Investigator
Timepoint [1] 0 0
Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 4.5 years
Secondary outcome [2] 0 0
Progression-free Survival As Assessed by Blinded Independent Central Review and Investigator
Timepoint [2] 0 0
Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 4.5 years
Secondary outcome [3] 0 0
Duration of Response As Assessed by Blinded Independent Central Review and Investigator
Timepoint [3] 0 0
From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 4.5 years
Secondary outcome [4] 0 0
Disease Control Rate As Assessed by Blinded Independent Central Review and Investigator
Timepoint [4] 0 0
Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 4.5 years
Secondary outcome [5] 0 0
Time to Response As Assessed by Blinded Independent Central Review and Investigator
Timepoint [5] 0 0
From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 4.5 years
Secondary outcome [6] 0 0
Change from Baseline in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30
Timepoint [6] 0 0
Baseline up to 4.5 years
Secondary outcome [7] 0 0
Change from Baseline in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 29 (EORTC QLQ-LC29)
Timepoint [7] 0 0
Baseline up to 4.5 years
Secondary outcome [8] 0 0
Overall Number of Participants With Treatment-emergent Adverse Events Following I-DXd Monotherapy
Timepoint [8] 0 0
Baseline up to 4.5 years
Secondary outcome [9] 0 0
The Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive At Any Time and Who Have A Treatment-emergent Anti-Drug Antibody
Timepoint [9] 0 0
Baseline up to 4.5 years
Secondary outcome [10] 0 0
Pharmacokinetic Parameter Maximum Concentration for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a
Timepoint [10] 0 0
Cycle 1 before infusion (BI), end of infusion EOI), and 3, 6, 24, 72, 168, 336, and 504 hours (hrs) post dose; Cycle 2 BI and EOI; Cycle 3 BI, EOI, and 6 hrs postdose; Cycles 4, 5, and every 2 cycles thereafter up to 4.5 years BI (each cycle is 21 days)
Secondary outcome [11] 0 0
Pharmacokinetic Parameter Time to Maximum Concentration for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a
Timepoint [11] 0 0
Cycle 1 before infusion (BI), end of infusion EOI), and 3, 6, 24, 72, 168, 336, and 504 hours (hrs) post dose; Cycle 2 BI and EOI; Cycle 3 BI, EOI, and 6 hrs postdose; Cycles 4, 5, and every 2 cycles thereafter up to 4.5 years BI (each cycle is 21 days)
Secondary outcome [12] 0 0
Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a
Timepoint [12] 0 0
Cycle 1 before infusion (BI), end of infusion EOI), and 3, 6, 24, 72, 168, 336, and 504 hours (hrs) post dose; Cycle 2 BI and EOI; Cycle 3 BI, EOI, and 6 hrs postdose; Cycles 4, 5, and every 2 cycles thereafter up to 4.5 years BI (each cycle is 21 days)

Eligibility
Key inclusion criteria
Inclusion Criteria

Participants must meet all the following criteria to be eligible for randomization into the
study:

1. Sign and date the informed consent form prior to the start of any study-specific
qualification procedures.

2. Adults =18 years or the minimum legal adult age (whichever is greater) at the time the
informed consent form is signed.

3. Has histologically or cytologically documented SCLC.

4. The participant must provide adequate baseline tumor samples with sufficient quantity
and quality of tumor tissue content.

5. Has received prior therapy with only one prior platinum-based line as systemic therapy
for SCLC with at least 2 cycles of therapy and a chemotherapy-free interval of >30
days.

6. Has at least 1 measurable lesion according to RECIST v1.1 as assessed by the
investigator.

7. Has documentation of radiological disease progression on or after the most recent
systemic therapy.

8. Has ECOG PS of =1.

9. Subjects with untreated and asymptomatic brain metastases or subjects with treated
brain metastases that are no longer symptomatic (ie, without neurologic signs or
symptoms) and who require no treatment with steroids or anticonvulsants may be
included in the study if they have recovered from the acute toxic effect of
radiotherapy. Subjects must have a stable neurologic status for at least 2 weeks prior
to the first dose of study drug.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the
study:

1. Has received prior treatment with orlotamab, enoblituzumab, or other humanized anti-B7
homologue 3 (B7-H3) targeted agents, including I-DXd.

2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan
derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.

3. Has received any of the comparators used in this study or any topoisomerase I
inhibitor.

4. Has inadequate washout period before randomization as specified in the protocol.

5. Has any of the following conditions within the past 6 months: cerebrovascular
accident, transient ischemic attack, or another arterial thromboembolic event.

6. Has uncontrolled or significant cardiovascular disease.

7. Has clinically significant corneal disease.

8. Has history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that
required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that
cannot be ruled out by imaging at Screening.

9. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary
illnesses, including, but not limited to, any underlying pulmonary disorder and
potential pulmonary involvement caused by any autoimmune, connective tissue, or
inflammatory disorders, prior pneumonectomy, or requirement for supplemental oxygen.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
10/06/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
22/02/2029
Actual
Sample size
Target
468
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Ballarat Base Hospital - Ballarat
Recruitment hospital [2] 0 0
Chris Oâ Brien Lifehouse - Camperdown
Recruitment hospital [3] 0 0
Sunshine Hospital - St Albans
Recruitment hospital [4] 0 0
St John of God Subiaco Hospital - Subiaco
Recruitment hospital [5] 0 0
Townsville Cancer Centre - Townsville
Recruitment hospital [6] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
3350 - Ballarat
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
3021 - St Albans
Recruitment postcode(s) [4] 0 0
6008 - Subiaco
Recruitment postcode(s) [5] 0 0
4814 - Townsville
Recruitment postcode(s) [6] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
Nebraska
Country [11] 0 0
United States of America
State/province [11] 0 0
New Hampshire
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Wisconsin
Country [20] 0 0
Belgium
State/province [20] 0 0
Brussels
Country [21] 0 0
Belgium
State/province [21] 0 0
Edegem
Country [22] 0 0
Belgium
State/province [22] 0 0
Hasselt
Country [23] 0 0
Belgium
State/province [23] 0 0
Liege
Country [24] 0 0
Belgium
State/province [24] 0 0
Roeselare
Country [25] 0 0
Belgium
State/province [25] 0 0
Yvoir
Country [26] 0 0
Brazil
State/province [26] 0 0
Barretos
Country [27] 0 0
Brazil
State/province [27] 0 0
FlorianAlpolis
Country [28] 0 0
Brazil
State/province [28] 0 0
ItajaA-
Country [29] 0 0
Brazil
State/province [29] 0 0
Porto Alegre
Country [30] 0 0
Brazil
State/province [30] 0 0
Santo Andre
Country [31] 0 0
Brazil
State/province [31] 0 0
Sao Jose Rio Preto
Country [32] 0 0
Brazil
State/province [32] 0 0
SALo Paulo
Country [33] 0 0
Canada
State/province [33] 0 0
Halifax
Country [34] 0 0
Canada
State/province [34] 0 0
Toronto
Country [35] 0 0
China
State/province [35] 0 0
Beijing
Country [36] 0 0
China
State/province [36] 0 0
Changchun
Country [37] 0 0
China
State/province [37] 0 0
Changsha
Country [38] 0 0
China
State/province [38] 0 0
Chengdu
Country [39] 0 0
China
State/province [39] 0 0
Chongqing
Country [40] 0 0
China
State/province [40] 0 0
Hangzhou
Country [41] 0 0
China
State/province [41] 0 0
Harbin
Country [42] 0 0
China
State/province [42] 0 0
Jinan
Country [43] 0 0
China
State/province [43] 0 0
Linyi
Country [44] 0 0
China
State/province [44] 0 0
Neijiang
Country [45] 0 0
China
State/province [45] 0 0
Shanghai
Country [46] 0 0
China
State/province [46] 0 0
Tianjin
Country [47] 0 0
China
State/province [47] 0 0
Urumqi
Country [48] 0 0
China
State/province [48] 0 0
Wuhan
Country [49] 0 0
China
State/province [49] 0 0
Xi'an
Country [50] 0 0
China
State/province [50] 0 0
Xiangyang
Country [51] 0 0
China
State/province [51] 0 0
Yantai
Country [52] 0 0
China
State/province [52] 0 0
Zhengzhou
Country [53] 0 0
France
State/province [53] 0 0
Avignon Cedex 9
Country [54] 0 0
France
State/province [54] 0 0
Bordeaux cedex
Country [55] 0 0
France
State/province [55] 0 0
Creteil Cedex
Country [56] 0 0
France
State/province [56] 0 0
Lille Cedex
Country [57] 0 0
France
State/province [57] 0 0
Limoges cedex
Country [58] 0 0
France
State/province [58] 0 0
Lyon
Country [59] 0 0
France
State/province [59] 0 0
Marseille
Country [60] 0 0
France
State/province [60] 0 0
Montpellier cedex 05
Country [61] 0 0
France
State/province [61] 0 0
Montpellier
Country [62] 0 0
France
State/province [62] 0 0
Mulhouse Cedex
Country [63] 0 0
France
State/province [63] 0 0
Paris Cedex 05
Country [64] 0 0
France
State/province [64] 0 0
Paris
Country [65] 0 0
France
State/province [65] 0 0
Rennes cedex 09
Country [66] 0 0
France
State/province [66] 0 0
Saint Herblain
Country [67] 0 0
France
State/province [67] 0 0
Saint-Priest-En-Jarez
Country [68] 0 0
France
State/province [68] 0 0
Suresnes Cedex
Country [69] 0 0
France
State/province [69] 0 0
Villejuif cedex
Country [70] 0 0
Germany
State/province [70] 0 0
Berlin
Country [71] 0 0
Germany
State/province [71] 0 0
Erfurt
Country [72] 0 0
Germany
State/province [72] 0 0
Essen
Country [73] 0 0
Germany
State/province [73] 0 0
Frankfurt am Main
Country [74] 0 0
Germany
State/province [74] 0 0
Frankfurt
Country [75] 0 0
Germany
State/province [75] 0 0
Gauting
Country [76] 0 0
Germany
State/province [76] 0 0
Gera
Country [77] 0 0
Germany
State/province [77] 0 0
Giessen
Country [78] 0 0
Germany
State/province [78] 0 0
Hamburg
Country [79] 0 0
Germany
State/province [79] 0 0
Immenhausen/Krs. Kassel
Country [80] 0 0
Germany
State/province [80] 0 0
Kiel
Country [81] 0 0
Germany
State/province [81] 0 0
Minden
Country [82] 0 0
Germany
State/province [82] 0 0
Oldenburg
Country [83] 0 0
Germany
State/province [83] 0 0
Ulm
Country [84] 0 0
Hungary
State/province [84] 0 0
Budapest
Country [85] 0 0
Hungary
State/province [85] 0 0
Gyor
Country [86] 0 0
Hungary
State/province [86] 0 0
Kecskemet
Country [87] 0 0
Italy
State/province [87] 0 0
Bari
Country [88] 0 0
Italy
State/province [88] 0 0
Bergamo
Country [89] 0 0
Italy
State/province [89] 0 0
Brescia
Country [90] 0 0
Italy
State/province [90] 0 0
Catania
Country [91] 0 0
Italy
State/province [91] 0 0
Catanzaro
Country [92] 0 0
Italy
State/province [92] 0 0
Genova
Country [93] 0 0
Italy
State/province [93] 0 0
Milano
Country [94] 0 0
Italy
State/province [94] 0 0
Monza
Country [95] 0 0
Italy
State/province [95] 0 0
Napoli
Country [96] 0 0
Italy
State/province [96] 0 0
Parma
Country [97] 0 0
Italy
State/province [97] 0 0
Perugia
Country [98] 0 0
Italy
State/province [98] 0 0
Roma
Country [99] 0 0
Italy
State/province [99] 0 0
Rozzano
Country [100] 0 0
Italy
State/province [100] 0 0
Verona
Country [101] 0 0
Japan
State/province [101] 0 0
Chuo-ku
Country [102] 0 0
Japan
State/province [102] 0 0
Fukuoka
Country [103] 0 0
Japan
State/province [103] 0 0
Kashiwa
Country [104] 0 0
Japan
State/province [104] 0 0
Koto-ku
Country [105] 0 0
Japan
State/province [105] 0 0
Matsuyama
Country [106] 0 0
Japan
State/province [106] 0 0
Okayama
Country [107] 0 0
Japan
State/province [107] 0 0
Osaka-Sayama
Country [108] 0 0
Japan
State/province [108] 0 0
Sagamihara
Country [109] 0 0
Japan
State/province [109] 0 0
Sapporo
Country [110] 0 0
Japan
State/province [110] 0 0
Sunto-gun
Country [111] 0 0
Japan
State/province [111] 0 0
Takatsuki
Country [112] 0 0
Japan
State/province [112] 0 0
Wakayama
Country [113] 0 0
Korea, Republic of
State/province [113] 0 0
Cheongju
Country [114] 0 0
Korea, Republic of
State/province [114] 0 0
Daegu
Country [115] 0 0
Korea, Republic of
State/province [115] 0 0
Goyan-si
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Seongnam-si
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Seoul
Country [118] 0 0
Korea, Republic of
State/province [118] 0 0
Suwon-si
Country [119] 0 0
Netherlands
State/province [119] 0 0
's Hertogenbosch
Country [120] 0 0
Netherlands
State/province [120] 0 0
Amsterdam
Country [121] 0 0
Netherlands
State/province [121] 0 0
Maastricht
Country [122] 0 0
Netherlands
State/province [122] 0 0
Tilburg
Country [123] 0 0
Poland
State/province [123] 0 0
Krakow
Country [124] 0 0
Poland
State/province [124] 0 0
Otwock
Country [125] 0 0
Poland
State/province [125] 0 0
Prabuty
Country [126] 0 0
Poland
State/province [126] 0 0
Tomaszow Mazowiecki
Country [127] 0 0
Portugal
State/province [127] 0 0
Coimbra
Country [128] 0 0
Portugal
State/province [128] 0 0
Guimarães
Country [129] 0 0
Portugal
State/province [129] 0 0
Lisboa
Country [130] 0 0
Romania
State/province [130] 0 0
Cluj Napoca
Country [131] 0 0
Romania
State/province [131] 0 0
Comuna Floresti
Country [132] 0 0
Romania
State/province [132] 0 0
Craiova
Country [133] 0 0
Romania
State/province [133] 0 0
Suceava
Country [134] 0 0
Spain
State/province [134] 0 0
Barcelona
Country [135] 0 0
Spain
State/province [135] 0 0
Cordoba
Country [136] 0 0
Spain
State/province [136] 0 0
Jaen
Country [137] 0 0
Spain
State/province [137] 0 0
Jerez De Frontera
Country [138] 0 0
Spain
State/province [138] 0 0
L'Hospitalet de Llobregat
Country [139] 0 0
Spain
State/province [139] 0 0
Las Palmas de Gran Canaria
Country [140] 0 0
Spain
State/province [140] 0 0
Madrid
Country [141] 0 0
Spain
State/province [141] 0 0
MAAlaga
Country [142] 0 0
Spain
State/province [142] 0 0
Sevilla
Country [143] 0 0
Switzerland
State/province [143] 0 0
Bern
Country [144] 0 0
Switzerland
State/province [144] 0 0
Fribourg
Country [145] 0 0
Switzerland
State/province [145] 0 0
St. Gallen
Country [146] 0 0
Taiwan
State/province [146] 0 0
Kaohsiung City
Country [147] 0 0
Taiwan
State/province [147] 0 0
Taichung
Country [148] 0 0
Taiwan
State/province [148] 0 0
Tainan
Country [149] 0 0
Taiwan
State/province [149] 0 0
Taipei
Country [150] 0 0
Taiwan
State/province [150] 0 0
Taoyuan County
Country [151] 0 0
Taiwan
State/province [151] 0 0
Tapei
Country [152] 0 0
Turkey
State/province [152] 0 0
Ankara
Country [153] 0 0
Turkey
State/province [153] 0 0
Diyarbakir
Country [154] 0 0
Turkey
State/province [154] 0 0
Istanbul
Country [155] 0 0
Turkey
State/province [155] 0 0
Izmir
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Birmingham
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Leeds
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Manchester
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Daiichi Sankyo
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study was designed to compare the efficacy and safety of I-DXd with treatment of
physician's choice in participants with relapsed small cell lung cancer (SCLC).
Trial website
https://clinicaltrials.gov/ct2/show/NCT06203210
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Director
Address 0 0
Daiichi Sankyo
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Daiichi Sankyo Contact for Clinical Trial Information
Address 0 0
Country 0 0
Phone 0 0
9089926400
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06203210